CymaBay Therapeutics (CBAY) Misses Q3 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
CymaBay Reports Third Quarter and Nine Months Ended September 30, 2023 Financial Results and Provides Corporate Update
November 7, 2023 4:04 PM ESTAnnounced top-line results from RESPONSE Phase 3 study in PBC where seladelpar met the primary and two key secondary endpoints with high statistical significance.
Seladelpar granted revised Breakthrough Therapy Designation for the treatment of PBC including pruritus in patients without cirrhosis or with compensated cirrhosis and are inadequate responders to or intolerant to UDCA.
Announced oral late-breaking presentation of results from the RESPONSE global Phase 3 study evaluating seladelpar for Primary Biliary Cholangitis at The Liver Meeting® 2023.
... More